Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company plc (NYSE: PRGO) is a pure-play self-care and consumer health company whose news flow is closely tied to its over-the-counter (OTC) product portfolio, category performance and strategic initiatives. The company regularly issues updates on its Consumer Self-Care Americas and Consumer Self-Care International segments, highlighting trends in categories such as Upper Respiratory, Pain & Sleep Aids, Digestive Health, Nutrition, Vitamins, Minerals and Supplements, Women’s Health, Skin Care, Oral Care and Healthy Lifestyle.
On this page, readers can follow Perrigo’s earnings announcements, where the company discusses net sales, organic growth, segment performance and the impact of divestitures and exited products. These releases often reference store brand market share gains in OTC categories, performance of key brands and progress under its Three-S plan (Stabilize, Streamline, Strengthen). Updates on Project Energize, the global investment and efficiency program designed to support the One Perrigo growth strategy, are also a recurring theme in recent communications.
Perrigo’s news also covers portfolio actions and strategic reviews. The company has disclosed an agreement to sell its Dermacosmetics branded business in certain European markets and has announced strategic reviews of its Oral Care and infant formula businesses. In addition, readers will find announcements related to dividends, participation in investor conferences and brand-level initiatives, such as collaborations involving Opill®, which Perrigo describes as the first daily birth control pill available without a prescription in the United States.
Investors, analysts and consumers can use this news feed to monitor how Perrigo is positioning its OTC and self-care portfolio, how its store brand and branded businesses are performing across regions and categories, and how management is adjusting the company’s structure and investments in response to market conditions.
Opill®, the first and only daily birth control pill available without a prescription in the U.S., announces a partnership with WNBA Star and Olympic Gold Medalist Napheesa Collier. This collaboration extends Opill's multi-year partnership with the WNBA. Collier, a mother and advocate for women's health, will participate in educational events on college campuses to raise awareness about Opill® and reproductive health options.
Developed by Perrigo, Opill® represents a significant advancement in women's healthcare, offering convenient and accessible contraception without the need for a healthcare provider visit. The partnership aims to empower women to take charge of their reproductive health and increase access to birth control.
Perrigo (NYSE: PRGO) announced a new partnership between Good Start® and Dr. Brown's® to launch an infant formula portfolio. The collaboration aims to provide trusted infant formula solutions like Soothe Pro™ and Gentle Pro™ with new packaging. Good Start® has been a reliable brand for over 50 years, while Dr. Brown's® is known for its top pediatrician-recommended baby bottles. The new formulas are designed to address tolerance concerns and offer complete nutrition. Soothe Pro™ contains probiotic L. reuteri, and Gentle Pro™ includes probiotic B. lactis. Additionally, Soy-ease Pro™ is formulated with plant-based proteins for babies with lactose sensitivity. These products are available at major retailers like Walmart and Amazon. Perrigo's strategy focuses on consumer-led innovation to enhance the feeding experience for families.
Perrigo Company plc (NYSE: PRGO) announced the closing of a registered public offering by its indirect wholly-owned finance subsidiary, Perrigo Finance Unlimited Company. The offering includes $715 million of 6.125% Senior Notes due 2032 and €350 million of 5.375% Senior Notes due 2032. The total net proceeds are estimated at approximately $1,076 million after fees and expenses.
Perrigo plans to use the proceeds to redeem all of its 4.375% Senior Notes Due 2026 and prepay a portion of the Term B Loans under its credit facilities. The Notes will be fully guaranteed by Perrigo and its subsidiaries that provide guarantees under Perrigo's credit facilities. BofA Securities, J.P. Morgan, Wells Fargo Securities, Morgan Stanley, and HSBC are involved as joint book-running managers for the offering.
Perrigo Company plc (NYSE: PRGO) has announced the pricing of a registered public offering by its finance subsidiary, Perrigo Finance Unlimited Company. The offering includes $715 million of 6.125% Senior Notes due 2032 and €350 million of 5.375% Senior Notes due 2032. Both notes are priced at 100.000% of their aggregate principal amount.
The notes will be fully guaranteed by Perrigo and its subsidiaries that provide guarantees under Perrigo's credit facilities. Perrigo intends to use the net proceeds to redeem all of its 4.375% Senior Notes Due 2026 and prepay a portion of the Term B Loans outstanding under its credit facilities. The offering is expected to close around September 17, 2024, subject to closing conditions.
Perrigo Company plc (NYSE: PRGO), a global leader in Consumer Self-Care Products, has appointed Charles Atkinson as Executive Vice President, General Counsel and Secretary. Atkinson, with nearly 25 years of experience in the regulated consumer self-care industry, joins Perrigo from Haleon plc, where he served as Interim General Counsel. His expertise includes advising on transactions, integrations, and managing regulated healthcare product lifecycles.
CEO Patrick Lockwood-Taylor expressed confidence in Atkinson's ability to advance Perrigo's vision. Atkinson will replace Todd Kingma, who came out of retirement to serve as Interim EVP, General Counsel & Secretary. Kingma will assist in the transition before resuming his retirement.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced that its President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Piper Sandler Growth Frontiers Conference on Tuesday, September 10 at 10:00 AM CDT. Interested parties can access the webcast on the Perrigo website.
Perrigo is known for offering over-the-counter (OTC) health and wellness solutions that empower consumers to proactively prevent or treat self-manageable conditions. This presentation at a growth-focused conference suggests that Perrigo may be looking to highlight its expansion strategies and market positioning in the consumer self-care sector.
Perrigo Company plc (NYSE: PRGO) has appointed Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer, a newly created position. Dr. Ball will be responsible for developing an enterprise-wide marketing strategy focusing on consumer needs and brand-building efforts. He brings over 15 years of global consumer goods experience from roles at Bayer Consumer Healthcare and Procter & Gamble.
Dr. Ball's appointment is expected to strengthen Perrigo's global over-the-counter business and support its blended-branded strategy. His unique combination of consumer goods expertise and scientific background (PhD in Biophysics and Genetics) is seen as valuable for innovation and sustainable practices in the company's 135-year history.
Perrigo reported Q2 2024 financial results, with net sales of $1.1 billion, down 10.7% year-over-year. Organic net sales decreased 9.1%, primarily due to lower infant formula sales and reduced demand in Upper Respiratory and Pain & Sleep Aids categories. Adjusted diluted EPS was $0.53, compared to $0.63 in Q2 2023. The company reaffirmed its fiscal 2024 adjusted diluted EPS outlook of $2.50-$2.65, despite updating its organic net sales growth outlook to -3% to -1% from the previous +1% to +3%. Perrigo is progressing with its Project Energize efficiency program, targeting $140-$170 million in annualized pre-tax savings by 2026. The company completed the divestment of its HRA Pharma Rare Diseases business on July 10, 2024.
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, has announced a quarterly dividend of $0.276 per share. The dividend is payable on September 17, 2024, to shareholders of record on August 30, 2024. Perrigo is a prominent provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers to prevent or treat self-manageable conditions.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present on Wednesday, August 14 at 3:30 PM EDT.
Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. Perrigo is known for offering over-the-counter (OTC) health and wellness solutions that empower consumers to proactively prevent or treat self-manageable conditions, enhancing individual well-being.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
